4D Molecular Therapeutics (FDMT) Institutional Ownership
13F filers reported holding 80.8% of 4D Molecular Therapeutics (FDMT) shares as of Sep 30, 2026, across 184 filers.
- Held by 13F filers
- 80.8%
- Sep 30, 2026
- 13F filers
- 184
- quarter ended Sep 30, 2026
- 13F value
- $836.4M
- 58.5M shares
- Quarter's fund flow
- Mild accumulation
- 29 new · 17 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | Bizily Scott | Chief Legal Officer | Acquired · Option exercise | 1,635 | $4.14 | ↗ |
| Oct 16, 2026 | Bizily Scott | Chief Legal Officer | Disposed · Open-market sale | 1,635 | $12.84 | ↗ |
| Oct 16, 2026 | Bizily Scott | Chief Legal Officer | Disposed · Option exercise | 1,635Stock Option (Right to Buy) | — | ↗ |
| Oct 5, 2026 | Kirn David | See Remarks | Disposed · Open-market sale | 58,061 | $12.92 | ↗ |
| Oct 5, 2026 | Kirn David | See Remarks | Disposed · Open-market sale | 272 | $13.61 | ↗ |
| Sep 16, 2026 | Bizily Scott | Chief Legal Officer | Acquired · Option exercise | 1,635 | $4.14 | ↗ |
| Sep 16, 2026 | Bizily Scott | Chief Legal Officer | Disposed · Open-market sale | 1,635 | $13.65 | ↗ |
| Sep 16, 2026 | Bizily Scott | Chief Legal Officer | Disposed · Option exercise | 1,635Stock Option (Right to Buy) | — | ↗ |
| Sep 14, 2026 | Kirn David | See Remarks | Disposed · Open-market sale | 58,333 | $13.90 | ↗ |
| Sep 1, 2026 | Bizily Scott | Chief Legal Officer | Acquired · Option exercise | 584 | $6.49 | ↗ |
| Sep 1, 2026 | Bizily Scott | Chief Legal Officer | Disposed · Open-market sale | 584 | $14.00 | ↗ |
| Sep 1, 2026 | Bizily Scott | Chief Legal Officer | Disposed · Option exercise | 584Stock Option (Right to Buy) | — | ↗ |
| Aug 19, 2026 | Kirn David | See Remarks | Acquired · Option exercise | 50,000 | $4.14 | ↗ |
| Aug 19, 2026 | Kirn David | See Remarks | Disposed · Open-market sale | 43,149 | $15.36 | ↗ |
| Aug 19, 2026 | Kirn David | See Remarks | Disposed · Open-market sale | 25,927 | $16.42 | ↗ |
| Aug 19, 2026 | Kirn David | See Remarks | Disposed · Option exercise | 50,000Stock Option (Right to Buy) | — | ↗ |
| Aug 17, 2026 | Bizily Scott | Chief Legal Officer | Acquired · Option exercise | 1,635 | $4.14 | ↗ |
| Aug 17, 2026 | Bizily Scott | Chief Legal Officer | Disposed · Open-market sale | 1,635 | $12.20 | ↗ |
| Aug 17, 2026 | Bizily Scott | Chief Legal Officer | Disposed · Option exercise | 1,635Stock Option (Right to Buy) | — | ↗ |
| Aug 13, 2026 | Bizily Scott | Chief Legal Officer | Acquired · Option exercise | 1,635 | $4.14 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of 4D Molecular Therapeutics do institutions hold?
13F filers reported holding 80.8% of 4D Molecular Therapeutics' shares as of Sep 30, 2026, across 184 filers.
How many 13F filers hold 4D Molecular Therapeutics?
4D Molecular Therapeutics was held by 184 13F filers as of Sep 30, 2026.
Not investment advice.

